Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process of myelin degradation that underlies MS. The company believes this technique could enhance the development of MS therapies, including its investigational candidate Lucid-MS. An Investigational New Drug (IND) submission for a Phase 2 trial of Lucid-MS was submitted to the U.S. Food and Drug Administration in March 2026.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is leading the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The imaging study’s progress is a critical step in validating a tool that could provide direct evidence of demyelination in living patients, potentially improving diagnosis and treatment monitoring for MS. The preliminary data’s sensitivity to gray matter lesions is particularly noteworthy, as gray matter damage is increasingly recognized as a key contributor to disability in MS.
For more information on Quantum BioPharma and its pipeline, visit the company’s newsroom at https://ibn.fm/QNTM. The full press release can be accessed at https://ibn.fm/4IZ0y.
